BioCentury
ARTICLE | Clinical News

Lifitegrast: Phase III data

November 2, 2015 8:00 AM UTC

Top-line data from the double-blind, U.S. Phase III OPUS-3 trial in about 700 patients with dry eye disease showed that twice-daily 5% lifitegrast met the primary endpoint of improving patient-reporte...